Preserved T cell but attenuated antibody response in MS patients on fingolimod and ocrelizumab following 2nd and 3rd SARS-CoV-2 mRNA vaccine

BACKGROUND: There is limited knowledge about T cell responses in patients with multiple sclerosis (MS) after 3 doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine. OBJECTIVES: Assess the SARS-CoV-2 spike antibody and T cell responses in MS patients and healthy controls...

Descripción completa

Detalles Bibliográficos
Autores principales: Conway, Sarah, Saxena, Shrishti, Baecher-Allan, Clare, Krishnan, Rajesh, Houtchens, Maria, Glanz, Bonnie, Saraceno, Taylor J, Polgar-Turcsanyi, Mariann, Bose, Gauruv, Bakshi, Rohit, Bhattacharyya, Shamik, Galetta, Kristin, Kaplan, Tamara, Severson, Christopher, Singhal, Tarun, Stazzone, Lynn, Zurawski, Jonathan, Paul, Anu, Weiner, Howard L, Healy, Brian C, Chitnis, Tanuja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086198/
https://www.ncbi.nlm.nih.gov/pubmed/37057191
http://dx.doi.org/10.1177/20552173231165196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086198/
https://www.ncbi.nlm.nih.gov/pubmed/37057191
http://dx.doi.org/10.1177/20552173231165196

Ejemplares similares